Biomarker in Lung Diseases

The recruitment status of this study is unknown because the information has not been verified recently.

Verified October 2009 by University of Heidelberg.
Recruitment status was Recruiting

Sponsor:

Information provided by:

University of Heidelberg

ClinicalTrials.gov Identifier:

NCT00989846

First received: October 5, 2009

Last updated: October 13, 2009

Last verified: October 2009

History of Changes

Purpose

Disease related biomarkers have been established decades ago, e.g. blood glucose for diabetes diagnosis and management. Their discovery has grown dramatically during the past decade and they have the potential to lead the physician in diagnosis -especially differential diagnosis - and therapy.

However, a specific serum-biomarker in lung diseases has not been established. Aim of the current study is to to measure lung specific proteins in the serum in patients with various lung diseases and to correlate those with disease severity, lung function and other laboratory results

Condition	Intervention
Lung Diseases	Other: biomarker

Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	Feasibility Study on Establishing Biomarkers in Lung Diseases

Further study details as provided by University of Heidelberg:

Primary Outcome Measures:

Serum biomarker expression [ Time Frame: 1 month ] [ Designated as safety issue: No ]

Biospecimen Retention: Samples Without DNA

Serum (blood)

Estimated Enrollment:	120
Study Start Date:	October 2009
Estimated Study Completion Date:	June 2010
Estimated Primary Completion Date:	March 2010 (Final data collection date for primary outcome measure)

Groups/Cohorts	Assigned Interventions
lung disease patients with various chronic or acute lung diseases	Other: biomarker measuring serum-biomarkers

Eligibility

Ages Eligible for Study:	18 Years to 90 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Patients with acute or chronic lung diseases

Criteria

Inclusion Criteria:

age >= 18
acute or chronic lung disease

Exclusion Criteria:

HIV
lactation or gestation

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00989846

Contacts

Contact: Michael Kreuter, MD

49 / 6221 / 396 ext 1201

michael.kreuter@thoraxklinik-heidelberg.de

Locations

Germany
Thoraxklinik Heidelberg, Dept. of Pneumology and Respiratory Critical care	Recruiting
Heidelberg, Germany, 69126
Contact: Michael Kreuter, MD 49 / 6221 / 396 ext 1201 michael.kreuter@thoraxklinik-heidelberg.de
Principal Investigator: Michael Kreuter, MD

Sponsors and Collaborators

University of Heidelberg

Investigators

Principal Investigator:	Michael Kreuter, MD	Thoraxklinik Heidelberg, Germany
Study Director:	Felix JF Herth, MD	Thoraxklinik Heidelberg Germany

More Information

Publications:

Tzouvelekis A, Pneumatikos I, Bouros D. Serum biomarkers in acute respiratory distress syndrome an ailing prognosticator. Respir Res. 2005 Jun 22;6:62. Review.

Tzouvelekis A, Kouliatsis G, Anevlavis S, Bouros D. Serum biomarkers in interstitial lung diseases. Respir Res. 2005 Jul 21;6:78. Review.

Responsible Party:	Dr. Michael Kreuter, Thoraxklinik Heidelberg
ClinicalTrials.gov Identifier:	NCT00989846 History of Changes
Other Study ID Numbers:	MK02
Study First Received:	October 5, 2009
Last Updated:	October 13, 2009
Health Authority:	Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by University of Heidelberg:

biomarker
lung disease

Additional relevant MeSH terms:

Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on May 23, 2013

To Top